Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Rimmyrah 10 mg/ml solution for injection {equilateral_black_triangle}

Active Ingredient:
ranibizumab
Company:  
Orion Pharma (UK) Limited See contact details
ATC code: 
S01LA04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs Audio/Video HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Rimmyrah CNV educational materials

Important safety information for patients treated with: RIMMYRAH (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV) secondary to pathological myopia
{pdf_link}

Rimmyrah nAMD educational materials

Important safety information for patients treated with: RIMMYRAH (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD)
{pdf_link}

Rimmyrah PDR/DMO educational materials

Important safety information for patients treated with: RIMMYRAH (ranibizumab) with proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO)
{pdf_link}

Rimmyrah RVO educational materials

Important safety information for patients treated with: RIMMYRAH (ranibizumab) with visual impairment due to retinal vein occlusion (RVO)

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Orion Pharma (UK) Limited
Company image
Address
Abbey Gardens, 4 Abbey Street, Reading, RG1 3BA, UK
Telephone
+44 (0)1635 520 300
Medical Information e-mail
[email protected]
Out of Hours Telephone
+44 (0)1635 520 300